Other treatments, well documented in SLE (e.g., belimumab, an anti-BAFF human monoclonal antibody, anifrolumab, a monoclonal antibody against type I interferon receptor subunit 1, etc.)could also present potential therapeutic options in SLE-associated CAPS [84]. Here, TNFSF13B is linked to systemic lupus erythematosus.